echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Treatment of EB virus-related tumors: Nanatinostat and valganciclovir joint program named FDA Orphan Drug

    Treatment of EB virus-related tumors: Nanatinostat and valganciclovir joint program named FDA Orphan Drug

    • Last Update: 2020-07-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    About 95 percent of adults worldwide areinfected with theEB virusInfections are usually asymptomatic, and the virus can lurk in small groups of lymphocytes throughout the patient's life cycleIn some cases, such cells may undergo a malignant transformation and becomelymphomaIn addition to lymphoma, the EB virus is also associated with a variety of solid tumors, including nasopharyngeal cancer andstomach cancerViracta Therapeutics, a pharmaceutical company that specializes in virus-related malignanciesthe, announced today that its combination of nanatinostat and valganciclovir has been named an orphan drug by the U.SFood and Drug AdministrationAdministration(
    FDA) to treat EB-related T-cell lymphoma The combination of nanatinostat and valganciclovir has previously been awarded the title of orphan medicine for the treatment of post-transplant lymphocytic disease, plasma cell lymphoma and aveh immunity oocyte T-cell lymphoma Nanatinostat (VRx-3996) is an oral histone deacetyl enzyme (HDAC) inhibitor developed by Viracta Nanatinostat is selective in specific type of work for class I HDAC, which is key to inducing latent viral genes in EB virus-related malignancies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.